EXACT Sciences Co. (EXAS) Holdings Raised by Bank of Montreal Can

Bank of Montreal Can raised its holdings in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 490.5% during the first quarter, HoldingsChannel.com reports. The fund owned 73,625 shares of the medical research company’s stock after buying an additional 61,156 shares during the period. Bank of Montreal Can’s holdings in EXACT Sciences were worth $6,377,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. First Hawaiian Bank raised its holdings in EXACT Sciences by 160.0% during the first quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 200 shares during the period. Karp Capital Management Corp bought a new stake in EXACT Sciences during the fourth quarter valued at about $38,000. Shine Investment Advisory Services Inc. raised its holdings in EXACT Sciences by 130.2% during the first quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 250 shares during the period. CWM LLC raised its holdings in EXACT Sciences by 777.1% during the fourth quarter. CWM LLC now owns 614 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 544 shares during the period. Finally, Hanson McClain Inc. raised its holdings in EXACT Sciences by 377.5% during the fourth quarter. Hanson McClain Inc. now owns 955 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 755 shares during the period. 89.87% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have commented on EXAS shares. BidaskClub cut EXACT Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 15th. Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a report on Thursday, January 17th. Canaccord Genuity raised their price target on EXACT Sciences from $87.00 to $95.00 and gave the company a “buy” rating in a report on Monday, January 14th. UBS Group raised their price target on EXACT Sciences from $100.00 to $109.00 and gave the company a “buy” rating in a report on Monday, January 28th. Finally, Craig Hallum set a $95.00 price objective on EXACT Sciences and gave the company a “buy” rating in a research report on Friday, February 22nd. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $108.45.

In other news, Director Katherine S. Zanotti sold 25,000 shares of the firm’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $92.81, for a total transaction of $2,320,250.00. Following the completion of the transaction, the director now owns 94,274 shares in the company, valued at $8,749,569.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jeffrey Thomas Elliott sold 2,447 shares of EXACT Sciences stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $93.20, for a total value of $228,060.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,201 shares of company stock valued at $5,543,493. Company insiders own 3.20% of the company’s stock.

Shares of EXACT Sciences stock opened at $102.24 on Friday. The stock has a market cap of $13.20 billion, a PE ratio of -75.18 and a beta of 1.84. The company has a quick ratio of 8.13, a current ratio of 8.39 and a debt-to-equity ratio of 1.02. EXACT Sciences Co. has a twelve month low of $47.78 and a twelve month high of $105.28.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.01). The firm had revenue of $162.00 million for the quarter, compared to analysts’ expectations of $153.07 million. EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The company’s revenue for the quarter was up 79.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.33) EPS. Analysts anticipate that EXACT Sciences Co. will post -2.13 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “EXACT Sciences Co. (EXAS) Holdings Raised by Bank of Montreal Can” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/exact-sciences-co-exas-holdings-raised-by-bank-of-montreal-can.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.